MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

BACKGROUND: Hormone therapy is the standard of care for newly diagnosed or recurrent prostate cancers. It uses anti-androgen agents, castration, or both to eliminate cancer promoting effect of testicular androgen. The p53 tumor suppressor controls a major pathway that can block cell proliferation or...

Descripción completa

Detalles Bibliográficos
Autores principales: Tovar, Christian, Higgins, Brian, Kolinsky, Kenneth, Xia, Mingxuan, Packman, Kathryn, Heimbrook, David C, Vassilev, Lyubomir T
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094321/
https://www.ncbi.nlm.nih.gov/pubmed/21539745
http://dx.doi.org/10.1186/1476-4598-10-49

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094321/
https://www.ncbi.nlm.nih.gov/pubmed/21539745
http://dx.doi.org/10.1186/1476-4598-10-49

Ejemplares similares